GGHC
IMNM icon

Gilder Gagnon Howe & Co’s Immunome IMNM Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.7M Sell
169,267
-5,594
-3% -$125K 0.04% 165
2025
Q4 		$3.76M Buy
174,861
+41,749
+31% +$733K 0.04% 164
2025
Q3 		$1.56M Buy
+133,112
New +$1.32M 0.02% 202

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Gilder Gagnon Howe & Co's IMNM Position: Q1 2026 in Review

Gilder Gagnon Howe & Co reduced its Immunome (IMNM) stake by 3.2% in Q1 2026, selling an estimated $125K and leaving 169,267 shares worth $3.7M. The position accounts for 0.04% of the portfolio, ranked #165.

Gilder Gagnon Howe & Co first reported a position in IMNM in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.76M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Gilder Gagnon Howe & Co held 169,267 shares of Immunome worth $3.7M as of Q1 2026.
  • Gilder Gagnon Howe & Co sold 5,594 Immunome shares in Q1 2026, an estimated $125K.
  • Immunome made up 0.04% of Gilder Gagnon Howe & Co's portfolio in Q1 2026, its #165 holding.
  • Gilder Gagnon Howe & Co first reported a position in Immunome in Q3 2025 and has held it in 3 quarters since.
  • Gilder Gagnon Howe & Co's Immunome position peaked at $3.76M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2026, filed 15 May 2026.